Financials Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
138.1 USD +1.75% Intraday chart for Ascendis Pharma A/S +1.67% +9.63%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,924 7,375 6,716 6,376 6,455 7,262 - -
Enterprise Value (EV) 1 5,326 6,748 6,138 6,149 6,601 7,713 7,645 7,197
P/E ratio -26.5 x -16.5 x -16.9 x -11 x -13.3 x -24.5 x -212 x 22.8 x
Yield - - - - - - - -
Capitalization / Revenue 443 x 1,061 x 863 x 125 x 24.2 x 17 x 10.2 x 6.03 x
EV / Revenue 398 x 970 x 789 x 120 x 24.7 x 18.1 x 10.7 x 5.98 x
EV / EBITDA -24.2 x -21 x -14.1 x -11.3 x -15.1 x -40.3 x 352 x 31.6 x
EV / FCF -28 x -23.2 x -13.9 x -12.1 x -14.1 x -44.4 x 404 x 57.9 x
FCF Yield -3.57% -4.32% -7.19% -8.3% -7.12% -2.25% 0.25% 1.73%
Price to Book 9.97 x 8.24 x 7.33 x 24.3 x -44.1 x 745 x 26.1 x 16.1 x
Nbr of stocks (in thousands) 47,740 54,006 56,755 55,872 56,568 57,350 - -
Reference price 2 124.1 136.6 118.3 114.1 114.1 126.6 126.6 126.6
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13.38 6.953 7.778 51.17 266.7 426.6 712.1 1,204
EBITDA 1 -220 -321.2 -436.4 -543.9 -436.6 -191.6 21.7 227.4
EBIT 1 -226.7 -330.6 -451.8 -561.8 -455.5 -206 -3.473 374.8
Operating Margin -1,695.1% -4,755.07% -5,808.59% -1,097.85% -170.79% -48.28% -0.49% 31.12%
Earnings before Tax (EBT) 1 -218.2 -419.2 -383.9 -577.8 -474.1 -284.5 -6.927 397.6
Net income 1 -218 -419 -383.6 -583.2 -481.4 -299.2 -18.09 334.7
Net margin -1,630.03% -6,025.53% -4,931.56% -1,139.63% -180.51% -70.13% -2.54% 27.79%
EPS 2 -4.690 -8.280 -7.000 -10.40 -8.550 -5.179 -0.5980 5.543
Free Cash Flow 1 -190.2 -291.4 -441.4 -510.2 -469.8 -173.5 18.9 124.3
FCF margin -1,421.72% -4,191.11% -5,674.38% -996.97% -176.14% -40.67% 2.65% 10.32%
FCF Conversion (EBITDA) - - - - - - 87.09% 54.64%
FCF Conversion (Net income) - - - - - - - 37.13%
Dividend per Share 2 - - - - - - - -
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4.897 6.828 6.16 15.29 22.9 33.59 47.39 48.03 137.7 95.89 87.84 106.1 139.7 169.1 190.4
EBITDA 1 -108.3 -123.6 -137.5 -140 - -139.1 - -129.7 -31.63 -44.67 -50.93 -42.22 -31 - -
EBIT 1 -112.6 -128 -141.9 -144.5 -147.4 -143.7 -140.8 -134.4 -36.61 -49.14 -67.8 -57.44 -31.99 -12.07 1
Operating Margin -2,298.98% -1,875.06% -2,303.46% -945.09% -643.72% -427.77% -297.17% -279.82% -26.59% -51.25% -77.19% -54.12% -22.9% -7.14% 0.53%
Earnings before Tax (EBT) 1 -106.2 -125.3 -81.37 -169.1 -202.1 -109.6 -121.9 -161.6 -81.09 -128.5 -70.98 -60.14 -37.88 8 9
Net income 1 -106.1 -125.5 -81.32 -169 -207.4 -110.9 -121.4 -162.2 -86.88 -131 -75.7 -65.16 -37.89 8 7
Net margin -2,165.86% -1,837.99% -1,320.11% -1,105% -905.91% -330.21% -256.23% -337.73% -63.09% -136.65% -86.18% -61.39% -27.12% 4.73% 3.68%
EPS 2 -1.870 -2.210 -1.460 -3.030 -3.700 -1.980 -2.160 -2.880 -1.540 -2.300 -1.326 -1.130 -0.6745 0.1500 0.1300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/2/22 5/11/22 8/10/22 11/2/22 2/16/23 4/27/23 9/5/23 11/7/23 2/7/24 5/2/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 146 451 383 -
Net Cash position 1 598 627 577 227 - - - 64.7
Leverage (Debt/EBITDA) - - - - -0.3345 x -2.355 x 17.66 x -
Free Cash Flow 1 -190 -291 -441 -510 -470 -174 18.9 124
ROE (net income / shareholders' equity) -49.7% -58.4% -44.5% -102% -818% - -110% 116%
ROA (Net income/ Total Assets) -43.8% -50.6% -37.2% - -50.3% -31.3% 13.7% 39.5%
Assets 1 497.8 828.3 1,032 - 957.7 956.4 -131.6 846.4
Book Value Per Share 2 12.40 16.60 16.10 4.700 -2.590 0.1700 4.850 7.880
Cash Flow per Share 2 -3.980 -5.360 -7.630 -8.840 -8.300 -3.610 0.5000 -
Capex 1 5.16 19.9 23.7 14.5 2.44 5.1 5.4 4.2
Capex / Sales 38.57% 285.63% 304.76% 28.31% 0.92% 1.2% 0.76% 0.35%
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
126.6 EUR
Average target price
167.1 EUR
Spread / Average Target
+32.01%
Consensus
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. Financials Ascendis Pharma A/S